S. Johansson

发表

The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation

U. Eriksson, K. Wåhlander, M. Hellgren, 2005, BJOG : an international journal of obstetrics and gynaecology.

No effect of encapsulation on the pharmacokinetics of warfarin

L. Ohlsson, K. Wåhlander, S. Johansson, 2005, Biopharmaceutics & drug disposition.

The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol

U. Eriksson, T. Sarich, R. Teng, 2004, Journal of clinical pharmacology.

Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

T. Andersson, U. Eriksson, E. Bredberg, 2003, Clinical pharmacokinetics.

In Silico Predictions and In Vivo Results of Drug–Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate

N. Edvardsson, M. Aunes, L. Frison, 2016, Clinical pharmacology in drug development.

Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Paul D. Martin, E. Lisbon, S. Oliver, 2014, Clinical Pharmacokinetics.

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study

F. Erlandsson, J. Parkinson, J. Oscarsson, 2020, The Journal of clinical endocrinology and metabolism.

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

G. Helmlinger, D. Boulton, Weifeng Tang, 2020, CPT: pharmacometrics & systems pharmacology.

Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors

G. Helmlinger, D. Boulton, Weifeng Tang, 2019, Diabetes, Obesity and Metabolism.

In Vitro Assessment of the Drug–Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters

Caroline A. Lee, T. Andersson, F. Erlandsson, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Preclinical and Healthy Volunteer Studies of Potential Drug–Drug Interactions Between Tenapanor and Phosphate Binders

Andrew G. Spencer, D. Charmot, K. Kozuka, 2016, Clinical pharmacology in drug development.

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers

S. Johansson, M. Knutsson, M. Leonsson-Zachrisson, 2016, Clinical and Experimental Nephrology.

Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.

R. Terkeltaub, F. Erlandsson, J. Parkinson, 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Prediction of drug-related morphological changes of the T wave

N. Edvardsson, M. Aunes-Jansson, L. Frison, 2010, Scandinavian cardiovascular journal : SCJ.

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants

F. Erlandsson, M. Gillen, T. Hunt, 2022, Pharmacology research & perspectives.

Tenapanor administration and the activity of the H+‐coupled transporter PepT1 in healthy volunteers

E. Lisbon, J. Palm, C. Hilgendorf, 2017, British journal of clinical pharmacology.

QT Response after a Test Dose and during Maintenance Therapy with AZD1305 in Patients with Atrial Fibrillation

K. Egstrup, L. Bergfeldt, L. Gullestad, 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.

U. Eriksson, K. Dunér, K. Wåhlander, 2011, International journal of clinical pharmacology and therapeutics.

Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

H. Mulec, O. Samuelsson, P. Attman, 2003, Clinical pharmacokinetics.

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

K. Bamberg, I. Squire, P. Greasley, 2022, Clinical and translational science.

Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor.

H. Lennernäs, P. Artursson, L. Lazorova, 2013, Molecular pharmaceutics.

Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

M. Åstrand, G. Chertow, G. Block, 2017, Journal of the American Society of Nephrology : JASN.

Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk

C. de Beaufort, H. Siljander, A. Hämäläinen, 2021, Diabetologia.

Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.

G. Block, P. Greasley, T. Rydén-Bergsten, 2016, Clinical journal of the American Society of Nephrology : CJASN.

Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study

S. Johansson, M. Knutsson, M. Leonsson-Zachrisson, 2017, Clinical pharmacology in drug development.

A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases

J. Leander, Mikael Sunnåker, U. Eriksson, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

G. Helmlinger, D. Boulton, Weifeng Tang, 2019, Diabetes, obesity & metabolism.

Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight

J. Leander, D. Rekić, S. Johansson, 2020, Clinical Pharmacokinetics.

Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men

U. Eriksson, L. Ohlsson, K. Wåhlander, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach

T. Andersson, B. Jones, Kajsa P. Kanebratt, 2017, Drug Metabolism and Disposition.

Food Does Not Affect the Pharmacokinetics of Tesaglitazar, a Novel Dual Peroxisome Proliferator‐Activated Receptor α/γ Agonist

S. Halldorsdottir, S. Johansson, H. Stenhoff, 2006 .

Clinical Pharmacology Modeling and Simulation in Drug Development

A. Berges, Chao Chen, A. Egnell, 2020 .

Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling

C. Gottfridsson, J. Parkinson, C. Dota, 2022, British Journal of Clinical Pharmacology.

Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects S

W. Vaes, Marta Pelay-Gimeno, Greggory J. Housler, 2023 .

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions

B. Stefánsson, M. Elebring, Marie Ahlqvist, 2017, Clinical pharmacology in drug development.